Pathogenic antibodies to AQP4: Neuromyelitis optica spectrum disorder (NMOSD)

Sukhvir K. Wright*, Evangeline Wassmer, Angela Vincent

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

NMOSD is a rare but severe relapsing remitting demyelinating disease that affects both adults and children. Most patients have pathogenic antibodies that target the central nervous system AQP4 protein. This review provides an update on our current understanding of the disease pathophysiology and describes the clinical, paraclinical features and therapeutic management of the disease.
Original languageEnglish
Article number183772
JournalBBA -Biomembranes
Volume1863
Issue number12
Early online date9 Sep 2021
DOIs
Publication statusE-pub ahead of print - 9 Sep 2021

Bibliographical note

© 2021, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Funding: SKW was funded by a Wellcome Trust Clinical Research Career Development Fellowship (216613/Z/19/Z) during this work.

Keywords

  • AQP4
  • Immunotherapy
  • MOGAD
  • NMOSD
  • Neuroinflammation
  • Neuronal antibodies

Fingerprint

Dive into the research topics of 'Pathogenic antibodies to AQP4: Neuromyelitis optica spectrum disorder (NMOSD)'. Together they form a unique fingerprint.

Cite this